Fig. 1From: Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulationSubject Disposition. *Or clinically relevant findings in transvaginal ultrasound. †Clinically relevant findingsBack to article page